In recent trading session, Gritstone Oncology, Inc. (NASDAQ:GRTS) saw 566,628 shares changing hands. Company’s recent per share price level of $7.43 trading at $0.3 or 4.37% at recent trade assigns it a market valuation of $275.76 Million. That current trading price of GRTs’ stock is at a discount of -74.43% from its 52-week high price of $12.96 and is indicating a premium of 27.05% from its 52-week low price of $5.42. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 623Million shares which gives us an average trading volume of 283.85 Million if we extend that period to 3-months.
For Gritstone Oncology, Inc. (GRTS), analysts’ consensus is at an average recommendation of Overweight while assigning it a mean rating of 1.9. Splitting up the data highlights that, out of 7 analysts covering the stock, none rated the stock as a Sell while 2 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 4 see the stock as a Buy. None analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.73 in the current quarter.
Gritstone Oncology, Inc. (NASDAQ:GRTS) trade information
Upright in the green today for gaining 4.37%, in the last five days GRTS remained trading in the green while hitting it’s week-highest on Friday, Jul 10 when the stock touched $7.52-0 price level, adding 0.27% to its value on the day. Gritstone Oncology, Inc.’s shares saw a change of -16.39% in year-to-date performance and have moved 13.98% in past 5-day. Gritstone Oncology, Inc. (NASDAQ:GRTS) showed a performance of 8.07% in past 30-days. Number of shares sold short was 3.45 Million shares which calculate 0.01 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $20.83 to the stock, which implies a rise of 180.35% to its current value. Analysts have been projecting $16 as a low price target for the stock while placing it at a high target of $31. It follows that stock’s current price would jump +317.23% in reaching the projected high whereas dropping to the targeted low would mean a loss of 115.34% for stock’s current value.
Gritstone Oncology, Inc. (GRTS) estimates and forecasts
Statistics highlight that Gritstone Oncology, Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lessened -8.75% of value to its shares in past 6 months, showing an annual growth rate of -2.49% while that of industry is 10.5. Apart from that, the company came lowering its revenue forecast for fiscal year 2020. The company is estimating its revenue growth to decline by -15.9% in the current quarter and calculating 9.1% increase in the next quarter. This year revenue growth is estimated to rise 13.4% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $1.24 Million for the same. And 6 analysts are in estimates of company making revenue of $1.24 Million in the next quarter that will end in September 01, 2020. Company posted $1.15 Million and $984Million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 7.8% while estimating it to be 26% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0% during past 5 years. In 2020, company’s earnings growth rate is likely to be around -26.8% while estimates for its earnings growth in next 5 years are of 0%
Gritstone Oncology, Inc. (NASDAQ:GRTS)’s Major holders
Insiders are in possession of 10.07% of company’s total shares while institution are holding 79.17% percent of that, with stock having share float percentage of 88.04%. Investors also watch the number of corporate investors in a company very closely, which is 106 institutions for Gritstone Oncology, Inc. that are currently holding shares of the company. FMR, LLC is the top institutional holder at GRTS for having 5.24 Million shares of worth $30.51 Million. And as of March 30, 2020, it was holding 14.07% of the company’s outstanding shares.
The second largest institutional holder is Svennilson Peter, which was holding about 3.1 Million shares on March 30, 2020. The number of shares represents firm’s hold over 8.33% of outstanding shares, having a total worth of $18.06 Million.
On the other hand, Fidelity Select Portfolios – Biotechnology and Fidelity Series Large Cap Stock Fund are the top two Mutual Funds which own company’s shares. As of April 29, 2020, the former fund manager was holding 1248800 shares of worth $8.75 Million or 3.35% of the total outstanding shares. The later fund manager was in possession of 885.56 Thousand shares on April 29, 2020, making its stake of worth around $6.21 Million in the company or a holder of 2.38% of company’s stock.